With extensive studies, including the present investigation, showing that HK2 is a master promoting factor in different stages of carcinogenesis (Supplementary Table 4), much efforts were put in exploring HK-mediated tumor inhibitors, despite that no potent drugs targeting HK2 are yet available in clinic (80–84). This evidence concerns the gene HK2 and neoplasm.